Metformin Use in Patients with eGFR 30–44 mL/min/1.73 m²

Dosing Recommendations Based on eGFR

Continue metformin but reduce the dose to approximately half of the maximum (≈ 1000 mg per day) when eGFR is 30–44 mL/min/1.73 m². This recommendation is a strong, guideline‑based recommendation from KDIGO 2022. 1
Do not discontinue metformin solely because eGFR is between 30 and 44 mL/min/1.73 m²; discontinuation is advised only when eGFR falls below 30 mL/min/1.73 m². (KDIGO 2022, strong recommendation) 2

Re‑measure eGFR every 3–6 months (instead of annually) for any patient whose eGFR is < 60 mL/min/1.73 m² while on metformin. (KDIGO 2022) 1
Check vitamin B12 levels if metformin therapy extends beyond 4 years, to detect possible deficiency. (KDIGO 2022; ADA 2025) 7

The incidence of metformin‑associated lactic acidosis remains exceedingly rare even at eGFR 30–45 mL/min/1.73 m²; metformin concentrations in such patients are only about 3 % of those observed in confirmed cases of lactic acidosis. (Observational pharmacokinetic study, moderate evidence) 8
At eGFR 30–44 mL/min/1.73 m², renal clearance of metformin falls by roughly 75 %, resulting in an approximate 2‑fold increase in serum drug levels. (Pharmacokinetic analysis, moderate evidence) 8
Halving the dose compensates for the reduced clearance, preserving therapeutic benefit while limiting exposure. (KDIGO 2022, strong recommendation) 5

Acute kidney injury (any new rise in serum creatinine or drop in eGFR) warrants temporary cessation of metformin until renal function stabilizes. (KDIGO 2022) 5

eGFR < 30 mL/min/1.73 m² – metformin should be stopped permanently. (KDIGO 2022, strong recommendation) 3

Add an SGLT2 inhibitor (if eGFR permits; most agents are usable down to 20–25 mL/min/1.73 m²) to achieve optimal cardiorenal protection in chronic kidney disease. (KDIGO 2022) 9
The combination of metformin plus an SGLT2 inhibitor provides synergistic cardiorenal benefits in CKD. (KDIGO 2022; moderate‑strength evidence) 6
If additional glycemic control is needed, consider a GLP‑1 receptor agonist, which generally requires no dose adjustment for CKD. (KDIGO 2022) 2

The KDIGO 2022 clinical practice guideline (nephrology) and the ADA 2025 standards of care both base all metformin dosing decisions on eGFR rather than serum creatinine thresholds, reflecting the most current evidence‑based approach. (KDIGO 2022; ADA 2025) [1][7]